DCx accelerates multi-modal ADC development

CAR-T Digest - August 2020

2 May 2025: DCx accelerates multi-modal ADC development

DCx Biotherapeutics has launched with a focus on developing multi-modal antibody-drug conjugates (MM-ADCs) targeting genetically-defined cancers
The company in-licensed Repare Therapeutics’ SNIPRx, SNIPRx-surf, and STEP2 discovery platforms, along with preclinical small molecule and antibody programs
DCx also acquired Repare’s laboratory facilities, equipment, and around 20 scientific staff to strengthen its R&D capabilities
DCx also acquired rights to Repare’s proprietary CRISPR, bioinformatics, and machine learning enabled platforms, now known collectively as the MuSic platform, for the identification of surfaceome targets specific to genetic lesions in tumors
The agreement includes upfront payments, equity, and potential milestone and royalty payments to Repare, though specific financial terms were not disclosed